Author | Toni K. Choueiri, MD | OncLive

Author | Toni K. Choueiri, MD


Dr. Choueiri on Results of the SAVOIR Trial in MET-Driven Papillary RCC

May 29, 2020


Toni K. Choueiri, MD, discusses results of the phase 3 SAVOIR trial evaluating the MET inhibitor savolitinib versus sunitinib in patients with MET-driven papillary renal cell carcinoma.

Dr. Choueiri on Phase I/II Data of MK-6482 in Advanced Clear Cell RCC

February 15, 2020


Toni K. Choueiri, MD, director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, and Jerome and Nancy Kohlberg Chair and professor of medicine, Harvard Medical School, discusses phase I/II results of a trial evaluating the oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma.

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

December 04, 2019


The current management of metastatic renal cell carcinoma reflects the progress of medical oncology throughout the past several decades. The standard of care has evolved from cytokine-based therapies to targeted molecular therapies and immune checkpoint inhibitor–based strategies.

Investigators Seek Expanded Use of Checkpoint Inhibitors in RCC

December 05, 2018


In contrast to the wide array of available therapies in the metastatic setting of renal cell carcinoma, in patients with localized disease, the results of trials investigating adjuvant systemic therapy after nephrectomy have so far been underwhelming.